Clinical trial · Interventional
Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour
Can Magnetic Resonance Imaging of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour (Can MRI-PREDICT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer is the most common cancer diagnosed in men in Canada. Magnetic resonance imaging (MRI) may become a valuable tool to non-invasively identify prostate cancer and assess its biological aggressiveness, which in turn will help doctors make better decisions about how to treat an individual patient's prostate cancer. Despite the promise of MRI for detecting and characterizing prostate cancer, there are several recognized limitations and challenges. These include lack of standardized interpretation and reporting of prostate MRI exams. The investigators propose to validate and improve a computer program computerized prediction tool that will use information from MR images to inform us how aggressive a prostate cancer is. The hypothesis is that this computer-aided approach will increase the reproducibility and accuracy of MRI in predicting the tumor biology information about the imaged prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRT Accuracy | Diagnostic Test | — | UNRESOLVED |
| MRT Stability | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prospective Cohort
- description
- Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).
- interventionNames
- Diagnostic Test: MRT Accuracy
- Diagnostic Test: MRT Stability
Primary outcomes (3)
- measure
- MRT Classification Change
- timeFrame
- Baseline, 8 weeks
- description
- Stability of participants' MRT classification (each of the five GG groups) between two shortly spaced MRIs.
- measure
- MRT Classification: Baseline
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: An appropriate diagnostic MRI-P, defined as: * Being performed on 3T MRI at the Halifax Infirmary Building * Taken place within 5 weeks of study enrolment * Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen * Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate An appropriate diagnostic biopsy, defined as: * Taken place within 2 months of the participant's MRI-P 1 * Taken place within 3 months of participant's study enrolment * Reports diagnosis of PCa * Reports a systematic assessment of the biopsy, assessing at least 12 cores * Reports at least on core involved with PCa and this core must anatomically localise to a nodule seen on MRI-P 1 Exclusion Criteria: * Past prostatic interventions which would influence the prostate's structure * Alterations to physiological testosterone levels * Inability to position one's self in a reproducible fashion for an MRI-P * Patient factors reported to produce significant artifact on MRI-P 1
References
Publications (10)
- BACKGROUNDEpstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. PMID 26492179
- BACKGROUNDWeinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1. PMID 26427566
- BACKGROUNDWestphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, Bathala TK, Bittencourt LK, Booker MT, Braxton VG, Carroll PR, Casalino DD, Chang SD, Coakley FV, Dhatt R, Eberhardt SC, Foster BR, Froemming AT, Futterer JJ, Ganeshan DM, Gertner MR, Mankowski Gettle L, Ghai S, Gupta RT, Hahn ME, Houshyar R, Kim C, Kim CK, Lall C, Margolis DJA, McRae SE, Oto A, Parsons RB, Patel NU, Pinto PA, Polascik TJ, Spilseth B, Starcevich JB, Tammisetti VS, Taneja SS, Turkbey B, Verma S, Ward JF, Warlick CA, Weinberger AR, Yu J, Zagoria RJ, Rosenkrantz AB. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020 Jul;296(1):76-84. doi: 10.1148/radiol.2020190646. Epub 2020 Apr 21. PMID 32315265
- BACKGROUNDChaddad A, Kucharczyk MJ, Niazi T. Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer. Cancers (Basel). 2018 Jul 28;10(8):249. doi: 10.3390/cancers10080249. PMID 30060575
- BACKGROUNDT JMC, Arif M, Niessen WJ, Schoots IG, Veenland JF. Automated Classification of Significant Prostate Cancer on MRI: A Systematic Review on the Performance of Machine Learning Applications. Cancers (Basel). 2020 Jun 17;12(6):1606. doi: 10.3390/cancers12061606. PMID 32560558